Actinium Pharmaceuticals Inc. (Delaware) (ATNM) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Actinium Pharmaceuticals Inc. (Delaware) (ATNM) is Neutral.

The composite score behind that read is +0.03, weighing +0.36 of bullish evidence against -0.25 bearish.

Actinium Pharmaceuticals Inc. (Delaware) last closed at $1.10, +1.85% on the session.

Against the IVW growth benchmark the position is +1.05% over the forecast window.

The read is built from 15 underlying insights — 2 bullish and 13 bearish.

Agreement across those insights is 87%.

20 graded predictions for ATNM so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Actinium Pharmaceuticals Inc. (Delaware) in the 98th percentile on valuation and the 95th percentile on return on equity, where 100 is best.

Actinium Pharmaceuticals Inc. (Delaware) is classified under Health Care / Biotechnology, with a market capitalisation of $33.96M.

StockMap tracks Actinium Pharmaceuticals Inc. (Delaware) as the 322nd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Actinium Pharmaceuticals Inc. (Delaware) ranks 72nd of 381 in the group, against a group median of -0.08.